SG Americas Securities
BCAX

SG Americas Securities’s Bicara Therapeutics BCAX Stock Holding History

SG Americas Securities’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
+46,492
New +$1.04M ﹤0.01% 1689
2026
Q1 		– Sell
-11,122
Closed -$187K – 3796
2025
Q4 		$187K Buy
+11,122
New +$190K ﹤0.01% 2956
2025
Q1 		– Sell
-8,411
Closed -$147K – 3823
2024
Q4 		$147K Buy
+8,411
New +$175K ﹤0.01% 2428

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SG Americas Securities's BCAX Position: Q2 2026 in Review

SG Americas Securities opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 46,492 shares worth $1.38M. The stake represents ﹤0.01% of the portfolio and ranks #1689 among its holdings. This is a return to the name: SG Americas Securities previously reported a position in BCAX as recently as Q4 2025.

SG Americas Securities first reported a position in BCAX in Q4 2024 and has held it in 3 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • SG Americas Securities held 46,492 shares of Bicara Therapeutics worth $1.38M as of Q2 2026.
  • Bicara Therapeutics was a new SG Americas Securities position in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1689 holding.
  • SG Americas Securities first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.